Neuroblastoma: Biology, prognosis, and treatment

被引:217
作者
Park, Julie R. [1 ,2 ]
Eggert, Angelika [3 ]
Caron, Huib [4 ]
机构
[1] Univ Washington, Sch Med, Div Hematol & Oncol, Seattle, WA 98105 USA
[2] Childrens Hosp & Reg Med Ctr, Seattle, WA 98105 USA
[3] Univ Childrens Hosp Essen, Dept Hematol Oncol, D-45122 Essen, Germany
[4] Emma Childrens Hosp AMC, Dept Pediat Oncol & Hematol, EKZ AMC, NL-1100 DE Amsterdam, Netherlands
关键词
D O I
10.1016/j.pcl.2007.10.014
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Neuroblastoma, a neoplasm of the sympathetic nervous system, is the second most common extracranial malignant tumor of childhood and the most common solid tumor of infancy. Neuroblastoma is a heterogeneous malignancy with prognosis ranging from near uniform survival to high risk for fatal demise. Neuroblastoma. serves as a paradigm for the prognostic utility of biologic and clinical data and the potential to tailor therapy for patient cohorts at low, intermediate, and high risk for recurrence. This article summarizes our understanding of neuroblastoma biology and prognostic features and discusses their impact on current and proposed risk stratification schemas, risk-based therapeutic approaches, and the development of novel therapies for patients at high risk for failure.
引用
收藏
页码:97 / +
页数:25
相关论文
共 126 条
[61]  
Jaboin J, 2002, CANCER RES, V62, P6756
[62]   The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent [J].
Jodele, S ;
Chantrain, CF ;
Blavier, L ;
Lutzko, C ;
Crooks, GM ;
Shimada, H ;
Coussens, LM ;
DeClerck, YA .
CANCER RESEARCH, 2005, 65 (08) :3200-3208
[63]   CURRENT URINARY MASS-SCREENING FOR CATECHOLAMINE METABOLITES AT 6 MONTHS OF AGE MAY BE DETECTING ONLY A SMALL PORTION OF HIGH-RISK NEUROBLASTOMAS - A CHROMOSOME AND N-MYC AMPLIFICATION STUDY [J].
KANEKO, Y ;
KANDA, N ;
MASEKI, N ;
NAKACHI, K ;
TAKEDA, T ;
OKABE, I ;
SAKURAI, M .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (12) :2005-2013
[64]   Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: The Pediatric Oncology Group experience - A Pediatric Oncology Group study [J].
Katzenstein, HM ;
Bowman, LC ;
Brodeur, GM ;
Thorner, PS ;
Joshi, VV ;
Smith, EI ;
Look, AT ;
Rowe, ST ;
Nash, MB ;
Holbrook, T ;
Alvarado, C ;
Rao, PV ;
Castleberry, RP ;
Cohn, SL .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2007-2017
[65]  
KOGNER P, 1993, CANCER RES, V53, P2044
[66]  
KREISSRNAN SG, 2007, 43 ANN M AM SOC CLIN
[67]   HIGHLY EFFECTIVE INDUCTION THERAPY FOR STAGE-4 NEUROBLASTOMA IN CHILDREN OVER 1 YEAR OF AGE [J].
KUSHNER, BH ;
LAQUAGLIA, MP ;
BONILLA, MA ;
LINDSLEY, K ;
ROSENFIELD, N ;
YEH, S ;
EDDY, J ;
GERALD, WL ;
HELLER, G ;
CHEUNG, NKV .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (12) :2607-2613
[68]   Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy [J].
Kushner, BH ;
Cheung, NKV ;
LaQuaglia, MP ;
Ambros, PF ;
Ambros, IM ;
Bonilla, MA ;
Gerald, WL ;
Ladanyi, M ;
Gilbert, F ;
Rosenfield, NS ;
Yeh, SDJ .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) :373-381
[69]   Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery [J].
Kushner, BH ;
Wolden, S ;
LaQuaglia, MP ;
Kramer, K ;
Verbel, D ;
Heller, G ;
Cheung, NKV .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) :2821-2828
[70]  
KUSHNER BH, 1986, CANCER-AM CANCER SOC, V57, P1887, DOI 10.1002/1097-0142(19860501)57:9<1887::AID-CNCR2820570931>3.0.CO